BCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioCryst Pharmaceuticals Inc (BCRX) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has positive long-term growth potential based on analyst ratings and strategic acquisitions, the current technical indicators, lack of recent trading signals, and mixed financial performance suggest holding off on investment until clearer positive momentum or catalysts emerge.
The MACD is negatively expanding (-0.15), indicating bearish momentum. RSI is at 35.149, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 8.729), with resistance at R1: 9.753. Overall, technical indicators suggest a weak trend with no immediate buy signal.
Analyst ratings are consistently positive, with price targets ranging from $14 to $22 and an Outperform rating from multiple firms. Strategic acquisitions, such as Astria Therapeutics, position the company for long-term growth. Orladeyo and navenibart have significant revenue potential, with peak sales expected to reach $900M and $1B, respectively.
The stock has shown a -2.77% decline in regular market trading and a -0.46% drop post-market. The MACD and RSI indicate weak momentum. Financial performance in Q4 2025 shows a significant drop in net income (-1017.50% YoY) and EPS (-961.54% YoY), despite revenue growth. No recent news or congress trading data provides additional support for a buy decision.
In Q4 2025, revenue increased by 209.09% YoY to $406.56M, and gross margin improved to 97.66% (+2.43% YoY). However, net income dropped significantly (-1017.50% YoY) to $245.85M, and EPS fell to 1.12 (-961.54% YoY), indicating profitability challenges.
Analysts maintain an Outperform rating with price targets ranging from $14 to $22. Positive sentiment is driven by strategic acquisitions and long-term growth potential, but short-term headwinds, such as seasonal impacts and macroeconomic factors, are noted.
